Stryker Corporation is a leading medical technology company that specializes in designing, manufacturing, and marketing innovative products and services for healthcare professionals and patients. The company offers a diverse range of medical devices, including surgical equipment, orthopedic implants, neurotechnology, and surgery assistance products. Stryker focuses on advancing healthcare through cutting-edge technology and solutions that enhance patient care, improve surgical outcomes, and streamline hospital operations. With a commitment to innovation and quality, Stryker plays a pivotal role in the medical industry, helping healthcare providers deliver effective treatment and improve the quality of life for patients around the world. Read More
What Happened? Shares of medical technology company Stryker (NYSE:SYK) jumped 3.2% in the afternoon session after investors appeared to buy the dip after the...
As of March 16, 2026, the medical technology landscape is grappling with a stark reminder of the vulnerabilities inherent in the digital shift of healthcare. Stryker Corporation (NYSE: SYK), a global titan in medical devices and equipment, finds itself at the center of a developing storm following a massive cyberattack that has sent ripples through [...]
Bloomberg reported on Thursday that the company’s ordering and shipping systems are still offline following a cyberattack, claimed by pro-Iranian digital activist group Handala, on Wednesday.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices &...
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
In a definitive sign that the medical technology sector has moved past its post-pandemic stagnation, Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for the third fiscal quarter of 2026. On February 17, 2026, the Dublin-based medical device giant announced total revenue of $9.017 billion,
On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for an enterprise value of approximately $14.5 billion. This transaction, structured as a mix of 73% cash
Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for its fiscal third quarter of 2026, marking a significant turning point for the medical technology giant. The results, released on February 17, 2026, surpassed analyst expectations and highlighted a robust recovery in elective procedure volumes and a
As the broader market grappled with a violent valuation reset in the technology sector, the health care industry emerged as a critical anchor for investors in early 2026. The Health Care Select Sector SPDR Fund (NYSE Arca: XLV) posted a robust 1.1% advance this week, standing in stark contrast
Today’s Date: February 17, 2026 Introduction Medtronic plc (NYSE: MDT) has long been the sleeping giant of the medical technology sector. For years, the Dublin-domiciled powerhouse was viewed by Wall Street as a stable but slow-moving conglomerate, hampered by its own scale and a fragmented organizational structure. However, the narrative has shifted dramatically in early [...]
In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The deal represents the largest acquisition for Boston Scientific in over two decades, signaling a transformative
February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left investors and analysts debating the future of high-growth medtech. For over a decade, Boston Scientific has been the gold standard for consistent execution and category [...]
Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders of record at the close of business on March 31, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The deal, announced in mid-January and currently the talk of Wall Street as we move into February 2026, marks one
Medical technology company Stryker (NYSE:SYK) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.4% year on year to $7.17 billion. Its non-GAAP profit of $4.47 per share was 1.7% above analysts’ consensus estimates.
